Immunocytochemical and pharmacological characterisation of P2-purinoceptor-mediated cell growth and death in PC-3 hormone refractory prostate cancer cells

被引:1
|
作者
Calvert, RC
Shabbir, M
Thompson, CS
Mikhailidis, DP
Morgan, RJ
Burnstock, G
机构
[1] Royal Free Hosp, Dept Urol, Bedford Hosp, London NW3 2QG, England
[2] Royal Free Hosp, Urol Res Registrar, London NW3 2QG, England
[3] UCL, Royal Free & Univ Coll, Sch Med, Dept Clin Biochem, London, England
[4] UCL, Royal Free & Univ Coll, Sch Med, Dept Urol, London, England
[5] UCL, Royal Free & Univ Coll, Sch Med, Dept Anat & Autonom,Neurosci Inst, London, England
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Extracellular nucleotides (e.g. adenosine 5'-triphosphate, ATP) influence biological processes via purinergic receptors. We characterised the P2-purinoreceptors in human hormone refractory prostate cancer (HRPC) cells (PC-3 cells). Results: 1. Immunofluorescent staining demonstrated P2X(3), P2X(4), P2X(5), P2X(7) and P2Y(2) receptors. 2. ATP inhibited cell growth by up to 91% over 72h. Pharmacological characterisation indicated a P2X-putinoreceptor-mediated response. 3. Comparable maximum growth inhibition was seen after either a single addition of 1mM or daily addition of 100mM ATP. ATP concentrations ([ATP]) returned to baseline levels within 24h if the initial [ATP] was less than or equal to100 muM, while [ATP] remained high for 72h if a single concentration of 1 mM was used. 4. ATP 1 mM significantly (p<0.001) increased the proportion of cells undergoing apoptosis from 0.27% (+/- 0.04%) to 5.28% (+/- 0.77%). Conclusion: Threshold concentrations of ATP inhibited HRPC cell growth in vitro via the activation of P2X-purinoreceptors. The role of nucleotides in the treatment of HRPC requires further investigation.
引用
收藏
页码:2853 / 2859
页数:7
相关论文
共 50 条
  • [31] INOSITOL HEXAPHOSPHATE INHIBITS GROWTH AND INDUCES DIFFERENTIATION OF PC-3 HUMAN PROSTATE-CANCER CELLS
    SHAMSUDDIN, AM
    YANG, GY
    CARCINOGENESIS, 1995, 16 (08) : 1975 - 1979
  • [32] MORPHOLOGICAL AND BIOCHEMICAL CHANGES OF A.PANICULATA-INDUCED CELL DEATH IN HUMAN PROSTATE CARCINOMA PC-3 CELLS
    Kim, Tan Guak
    Hwi, Kim Kah
    Hung, Cheah Swee
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3646 - 3647
  • [33] Corn silk maysin induces apoptotic cell death in PC-3 prostate cancer cells via mitochondria-dependent pathway
    Lee, Jisun
    Lee, Seul
    Kim, Sun-Lim
    Choi, Ji Won
    Seo, Jeong Yeon
    Choi, Doo Jin
    Park, Yong Il
    LIFE SCIENCES, 2014, 119 (1-2) : 47 - 55
  • [34] The Expressions of Androgen Receptors in PC-3 Prostate Cancer Cells Reactivated by As2O3
    李小民
    樊青霞
    赵培荣
    王瑞林
    王留兴
    肿瘤基础与临床, 2006, (04) : 294 - 296
  • [35] Fenretinide: Induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells
    Roberson, KM
    Penland, SN
    Padilla, GM
    Selvan, RS
    Kim, CS
    Fine, RL
    Robertson, CN
    CELL GROWTH & DIFFERENTIATION, 1997, 8 (01): : 101 - 111
  • [36] Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol
    Marvin Rubenstein
    Leonid Slobodskoy
    Yelena Mirochnik
    Patrick Guinan
    Medical Oncology, 2003, 20 : 29 - 35
  • [37] Modulation of growth and apoptosis response in PC-3 and LNCaP prostate-cancer cell lines by Fas
    Takeuchi, T
    Sasaki, Y
    Ueki, T
    Kaziwara, T
    Moriyama, N
    Kawabe, K
    Kakizoe, T
    INTERNATIONAL JOURNAL OF CANCER, 1996, 67 (05) : 709 - 714
  • [38] Effects of PTX1 expression on growth and tumorigenicity of the prostate cancer cell line PC-3
    Liu, XH
    Daskal, I
    Kwok, SCM
    DNA AND CELL BIOLOGY, 2003, 22 (07) : 469 - 474
  • [39] Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse
    Soos, G
    Jones, RF
    Haas, GP
    Wang, CY
    ANTICANCER RESEARCH, 1997, 17 (6D) : 4253 - 4258
  • [40] Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol
    Rubenstein, M
    Slobodskoy, L
    Mirochnik, Y
    Guinan, P
    MEDICAL ONCOLOGY, 2003, 20 (01) : 29 - 35